SIGA Technologies (SIGA) Q2 2026 earnings review
Revenue Surges Sequentially, But a Major Contract Cliff Looms
SIGA broke a three-quarter streak of operating losses with $41.0 million in Q2 total revenue, a Reversing trend sequentially but a severe Decelerating trend year-over-year (-49.5% vs 25Q2). The quarter was driven by $37 million in TPOXX deliveries: $24 million of IV TPOXX to the U.S. stockpile and $13 million of oral TPOXX internationally. However, a critical red flag has emerged: the U.S. delivery completed the final procurement order under the 19C BARDA contract. With no new long-term U.S. agreement announced, visibility into future revenue has functionally evaporated. While international execution was strong, SIGA's earnings remain highly volatile and dependent on unpredictable government procurement cycles.
🐂 Bull Case
The company successfully delivered $13 million of oral TPOXX to two international customers, validating management's prior guidance for 2026 international expansion and proving the drug's global biodefense appeal.
SIGA generated $13.9 million in operating income on $41.0 million in sales. The core business model remains an incredibly high-margin cash machine when government stockpiling orders are executed.
🐻 Bear Case
Q2 deliveries completed the absolute last procurement order under the 19C BARDA contract. Without a new comprehensive RFP and contract award from the U.S. government, domestic product revenue will plummet.
Despite the sequential surge, revenue is down nearly 50% year-over-year, and net income fell 65% (from $35.5M to $12.5M). The lumpiness of the business masks a structural decline in recent stockpiling volume.
⚖️ Verdict: 🔴
Bearish. Generating $41 million in revenue is a positive sequential step, but completing the final 19C BARDA contract order without a replacement in hand is a massive structural risk. Until a new U.S. government contract is signed, the stock is uninvestable for those seeking predictable earnings.
Key Themes
BARDA 19C Contract Exhausted
The most critical data point in the release is a single sentence: 'These deliveries completed the last procurement order under the 19C contract.' The U.S. government partnership is SIGA's foundational revenue driver. Entering the second half of 2026 without a signed replacement contract leaves the company entirely exposed to unpredictable, lumpy international orders. This contradicts the positive narrative of the $24 million Q2 delivery.
International Expansion Hits Targets
International sales are Accelerating, with $13 million of oral TPOXX delivered to two international customers in Q2. This perfectly matches the guidance from previous quarters regarding a 2026 Asia-Pacific order. With the recent Hikma MENA partnership, SIGA is successfully diversifying its geographic footprint, albeit at a smaller scale than U.S. orders.
Massive YoY Profitability Compression
While management highlighted product deliveries, operating income Decelerated dramatically, dropping 70% from $45.7M in 25Q2 to $13.9M in 26Q2. The operating margin compressed from roughly 56% to 34%. Management attributed this to 'different product mixes', likely reflecting lower-margin international sales or differing formulations compared to the massive 25Q2 U.S. oral deliveries.
Aggressive Capital Returns Dent Cash Position
SIGA's cash balance dropped from $155.0M at the end of 2025 to $117.6M in 26Q2. This was heavily driven by the $0.60 per share special cash dividend paid in April 2026 (an outflow of roughly $43 million). While shareholder-friendly, executing this payout right before the U.S. government contract expires reduces their financial flexibility.
R&D Revenue Pipeline Advancing
R&D revenue was Stable, coming in at $3.1 million for the quarter (up from $2.0 million YoY). This reflects ongoing BARDA-funded development, specifically the TPOXX pediatric powder formulation and Post-Exposure Prophylaxis (PEP) indications. Expanding the label is critical to increasing the Total Addressable Market (TAM) for future government stockpiling.
Macro Geopolitical & Regulatory Uncertainty
The biodefense market relies entirely on macro government policy and defense budgets. In Europe, the EMA's ongoing scrutiny regarding mpox efficacy remains a regulatory overhang. Furthermore, shifting U.S. administration policies or delays in HHS/ASPR decision-making directly stall SIGA's domestic contract renewals, making macro risk a primary operational bottleneck.
Technological Evolution of TPOXX
Beyond standard adult oral/IV treatments, SIGA's innovation engine relies on form-factor adaptations. The ongoing development of a pediatric oral suspension powder addresses a critical unmet vulnerability in national defense stockpiles, forcing governments to eventually place new, distinct orders.
Other KPIs
Down from $155.0 million at the end of 2025. The decline is almost entirely attributable to the $0.60 per share special dividend paid in Q2. Despite the drop, the balance sheet remains debt-free and liquid enough to absorb the lumpy revenue cycles.
Cost of sales remained high relative to revenue compared to the prior year. In 26Q2, COGS was 42.8% of total revenue, whereas in 25Q2 it was only 31.5%. This shift in product mix margins limits bottom-line conversion even when deliveries occur.
A return to tax expense following several quarters of tax benefits due to net losses. The effective tax rate on $14.9 million of pre-tax income was approximately 16%, a favorable rate that helped bolster the bottom line.
Guidance
Decelerating visibility. Management did not provide any specific revenue, earnings, or delivery guidance for H2 2026. Because the final US stockpiling order under the 19C contract was fulfilled, analysts are flying completely blind on domestic revenue for the remainder of the year.
Key Questions
Status of U.S. Government RFP
With the final delivery under the 19C BARDA contract now complete, what is the exact timeline and status of negotiations for a new long-term U.S. stockpiling agreement? Have there been any delays related to federal budget constraints?
Margin Compression Factors
Operating margins dropped significantly year-over-year despite the $41 million in revenue. Can you break down the specific mix differences between the U.S. IV deliveries and the international oral deliveries that caused this compression?
EMA Regulatory Update
What is the latest feedback from the EMA's CHMP regarding the mpox efficacy review, and how is this impacting ongoing negotiations for European international orders in H2 2026?
Visibility into H2 2026 International Sales
With U.S. orders currently exhausted, what is the hard backlog of international orders slated for delivery in the third and fourth quarters of 2026?